NeuraLight presents at the International Parkinson and Movement Disorder Society (MDS) Congress 2024

NeuraLight participated in the MDS Congress 2024 (September 27 – October 1, Philadelphia), where leading neurologists from Rush University Medical Center and Beilinson – Rabin Medical Center presented new clinical findings generated using NeuraLight’s platform.

Research Highlights

• Clinicians from Rush University Medical Center presented results from the PALOMA clinical trial, evaluating cognitive status in Parkinson’s disease using the NeuraLight’s platform.
• Neurologists from Beilinson – Rabin Medical Center presented work on oculometric differences between LRRK2-associated and idiopathic Parkinson’s disease, further validating NeuraLight’s ability to detect subtle disease-specific signatures.

Significance

The presentations demonstrate the value of NeuraLight’s biomarkers for capturing sensitive, objective measures of neurological function. By supporting both disease monitoring and stratification, these findings highlight the platform’s growing role in clinical research and trial design for Parkinson’s disease.